Literature DB >> 7285851

[The new versus the old antidepressant drugs: a comparative study of their psychopharmacological profiles (author's transl)].

M Bourin, A J Puech, R Chermat, L Doare, M Poncelet, P Simon.   

Abstract

We studied 13 known or potential antidepressants, choosen in different pharmacological classes: desipramine, imipramine, nialamide, dexamphetamine, AHR 1118, amineptine, iprindole, mianserine, nomifensine, salbutamol, TRH viloxazine, zimelidine. Each of these compounds was studied on 8 psychopharmacological tests: motor activity, reserpine induced hypothermia, reserpine induced ptosis, oxotremorine induced hypothermia, oxotremorine induced tremors, high doses apomorphine induced hypothermia, potentiation of toxic effects of yohimbine, behavioural despair. Clinical active compounds are efficient on yohimbine test and at least on one model of hypothermia; with a few exceptions, easy to explain, substances with a clearly demonstrated antidepressant activity in human have some common effects; these common effects can be used to predict, from animal experiments, an antidepressant effect in man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285851

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  3 in total

1.  Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant.

Authors:  A Stenger; J P Couzinier; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity.

Authors:  M Bourin; M C Colombel; M Malinge; J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1991-11       Impact factor: 6.186

3.  Comparison of the effects of three indirect dopamine agonists, GK 13, GBR 12783 and dexamphetamine on behavioural tests involving central catecholaminergic transmissions.

Authors:  D Duterte-Boucher; J M Kamenka; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.